Short answer
Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition). $180.0M base equity offering: 16,744,187 shares at $10.75 each.
Intellia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $180.0M base equity offering: 16,744,187 shares at $10.75 each
- Underwriters exercised full 2,511,628-share option, increasing total shares sold to 19,255,815
- Net proceeds approximately $194.6M for clinical development, commercial preparation, pipeline research, acquisitions, and working capital
- Funding runway extended at least into 2028, excluding potential product revenue and collaboration milestones
- Dilution and added capital support development ahead of potential hereditary angioedema approval in first half of 2027
Item 2.02 · Results of Operations and Financial Condition
- Forward-looking disclosure tied to Intellia’s anticipated public offering
- Potential offering proceeds and cash runway depend on market conditions and execution
- Lonvoguran ziclumeran approval remains subject to clinical, regulatory, and commercial risks
- Investors should review the offering prospectus and latest Form 10-K risk factors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Intellia Therapeutics, Inc. 8-K filings
Get the next NTLA 8-K as it lands
Follow NTLA for push alerts, or ask the research agent what this filing means.